Deep Health AI India Ltd Valuation Shifts Signal Heightened Price Risk

Valuation Metrics and Market Context

As of 17 June 2026, Deep Health AI India Ltd trades at ₹2.35 per share, up 3.98% from the previous close of ₹2.26. The stock’s 52-week range remains wide, with a high of ₹10.29 and a low of ₹1.65, reflecting significant volatility over the past year. Despite the recent uptick, the company’s year-to-date return stands at a steep -60.03%, markedly underperforming the Sensex’s -9.87% over the same period. Over longer horizons, the stock’s performance is even more concerning, with a three-year return of -70.77% against the Sensex’s robust 21.18% gain.

These figures underscore the challenges Deep Health AI faces in regaining investor confidence amid sector headwinds and company-specific issues. The micro-cap status further accentuates the stock’s risk profile, with liquidity and market perception playing critical roles in valuation.

Price-to-Earnings and Price-to-Book Value Analysis

The company’s current price-to-earnings (P/E) ratio stands at 4.96, which, on the surface, appears low compared to peers such as Khazanchi Jewell (P/E 17.27) and Asian Star Co. (P/E 24.24). However, this low P/E is not necessarily indicative of undervaluation but rather reflects the market’s cautious stance given the company’s deteriorated fundamentals and weak earnings visibility.

Price-to-book value (P/BV) is another critical metric where Deep Health AI registers 0.67, suggesting the stock trades below its book value. While this might attract value investors, it also signals concerns about asset quality or future profitability. In comparison, peers like Shanti Gold and Radhika Jeweltec exhibit higher P/BV multiples aligned with their stronger operational metrics and market positioning.

Enterprise Value Multiples and Profitability Ratios

Enterprise value to EBITDA (EV/EBITDA) and EV to EBIT ratios for Deep Health AI are both at 7.61, which are moderate but still reflect a valuation premium relative to some very attractive peers such as T B Z (EV/EBITDA 5.78) and Manoj Vaibhav (EV/EBITDA 6.12). The company’s EV to sales ratio of 5.96 further highlights the market’s expectation of revenue generation, though tempered by the company’s recent financial performance.

Profitability metrics reveal a return on capital employed (ROCE) of 7.83% and a return on equity (ROE) of 13.41%. While these figures are positive, they lag behind industry leaders and fail to inspire confidence in sustainable earnings growth. The dividend yield of 4.22% offers some income appeal but may not compensate for the underlying valuation risks.

Mojo Score and Rating Changes

MarketsMOJO’s proprietary scoring system assigns Deep Health AI a Mojo Score of 27.0, categorising it as a Strong Sell. This represents a downgrade from a previous Sell rating on 12 December 2025, reflecting deteriorating fundamentals and valuation concerns. The valuation grade has shifted from expensive to very expensive, signalling that despite low absolute multiples, the stock is considered overvalued relative to its risk and return profile.

Comparative Valuation Within the Sector

When benchmarked against peers in the Gems, Jewellery and Watches sector, Deep Health AI’s valuation metrics reveal a complex picture. While its P/E ratio is lower than many competitors, this is offset by its weak returns and micro-cap status, which elevate risk. For instance, Shanti Gold, rated as Attractive, trades at a P/E of 10.31 and EV/EBITDA of 8.95, suggesting a premium justified by stronger fundamentals.

Other companies such as T B Z and Renaissance Global are rated Very Attractive with P/E ratios of 6.43 and 12.43 respectively, and EV/EBITDA multiples below 9. These firms demonstrate better operational efficiency and growth prospects, which justify their valuation premiums. Deep Health AI’s PEG ratio of 0.05 is notably low, but this is reflective of depressed earnings expectations rather than growth potential.

Stock Price Volatility and Trading Range

The stock’s recent trading range, with a day’s high of ₹2.43 and low of ₹2.10, indicates some short-term buying interest. However, the wide 52-week range from ₹1.65 to ₹10.29 highlights significant volatility and investor uncertainty. This volatility is compounded by the company’s underwhelming returns over one, three, and five-year periods, which have failed to keep pace with the broader market.

Investment Outlook and Risk Considerations

Given the current valuation and financial metrics, Deep Health AI India Ltd remains a high-risk proposition. The downgrade to a Strong Sell rating by MarketsMOJO reflects concerns over earnings sustainability, valuation premium relative to risk, and poor relative performance. Investors should weigh these factors carefully against their risk appetite and portfolio objectives.

Conclusion: Valuation Attractiveness Diminished

Deep Health AI India Ltd’s shift from expensive to very expensive valuation status, despite low absolute multiples, signals a deteriorating investment case. The company’s weak returns relative to the Sensex, combined with modest profitability and micro-cap risks, have led to a strong sell recommendation. While the stock’s low P/E and P/BV might superficially suggest value, these metrics are overshadowed by fundamental weaknesses and market scepticism.

Investors seeking exposure to the Gems, Jewellery and Watches sector may find more compelling opportunities among peers with stronger financials and more attractive valuations. Deep Health AI’s current profile suggests caution and a need for thorough due diligence before considering any investment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today